Literature DB >> 3508537

Computer-aided dosage form design. I. Methods for defining a long-acting first-order delivery system of maximum formulating flexibility.

T Y Lee1, R E Notari.   

Abstract

The method provides an a priori assessment of the maximum allowable flexibility in the rate of release from a prolonged-release formulation. The clinical pharmacokinetic parameters describing the drug candidate are employed to calculate the ranges of rate constants and doses required for the formulation to provide a selected therapeutic duration. For a given patient, there may be an infinite number of combinations of release rate constants and dose sizes which will maintain steady-state plasma drug concentrations within a desired range when the formulation is administered at the selected dosing interval. Computer simulations of steady-state plasma concentrations are employed to establish the ranges for all of the acceptable rate constants and doses for each member of a group. The entire group is then examined to define the range of release rate constants and doses which would provide a useful formulation for every member in the group. Literature values for theophylline clinical pharmacokinetics in children and adults have been employed to illustrate the application of this method. The method is unique in that it provides an entire range of release rates on which to gauge the feasibility for success.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3508537     DOI: 10.1023/a:1016445220140

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Influence of diet and fluid on bioavailability of theophylline.

Authors:  P G Welling; L L Lyons; W A Craig; G A Trochta
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

2.  Pharmacokinetic analysis of the effect of theophylline on pulmonary function in asthmatic children.

Authors:  G Levy; R Koysooko
Journal:  J Pediatr       Date:  1975-05       Impact factor: 4.406

3.  Pharmacokinetics of theophylline in children with asthma.

Authors:  E F Ellis; R Koysooko; G Levy
Journal:  Pediatrics       Date:  1976-10       Impact factor: 7.124

4.  Pharmacokinetics of intravenous theophylline.

Authors:  P A Mitenko; R I Ogilvie
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets.

Authors:  H S Kaumeier; O H Kehrhahn; G Neugebauer; D Schuppan; J A Schwarz; A H Staib
Journal:  Arzneimittelforschung       Date:  1984

Review 6.  Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications.

Authors:  J G Wagner
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

7.  Pharmacokinetics and dose regimen of oral theophylline in children.

Authors:  P Bolme; M Eriksson; G Lönnerholm; L Paalzow
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1982-11

8.  Pharmacokinetic analysis of the disposition of intravenous theophylline in young children.

Authors:  P M Loughnan; D S Sitar; R I Ogilvie; A Eisen; Z Fox; A H Neims
Journal:  J Pediatr       Date:  1976-05       Impact factor: 4.406

  8 in total
  2 in total

1.  Computer-aided dosage form design. II. Methods for defining a zero-order sustained-release delivery system of maximum formulating flexibility.

Authors:  T Y Lee; R E Notari
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

2.  Computer-aided dosage form design. III. Feasibility assessment for an oral prolonged-release phenytoin product.

Authors:  J R Irvin; R E Notari
Journal:  Pharm Res       Date:  1991-02       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.